Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl
申请人:Università Degli Studi Di Milano - Bicocca
公开号:EP2161271A1
公开(公告)日:2010-03-10
The present invention relates to compounds of formula (I)
wherein R1, R2 and R3 are as defined in the description,
to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
The Application of Vinamidinium Salt to the Synthesis of 3-Chloro-α-carbolines
作者:Guangyu Xu、Shaixiao Tian、Yu Mao、Yongjun Jiang
DOI:10.1055/s-0037-1609151
日期:2018.4
A convenient synthesis of 3-chloro-α-carbolines by the condensation of vinamidinium salt with 2-indolinones via two steps is reported. This protocol has the advantages of readily available starting materials, high yields and easy workup.
ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL
申请人:Gambacorti Passerini Carlo
公开号:US20110281862A1
公开(公告)日:2011-11-17
The present invention relates to compounds of formula (I)
wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).
[EN] ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL<br/>[FR] INHIBITEURS DE NPM-ALK, RET, ET BCR-ABL À BASE D'ALPHA-CARBOLINE
申请人:UNIV MILANO BICOCCA
公开号:WO2010025872A2
公开(公告)日:2010-03-11
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).